Education
About Us
Working with TipRanks
Follow Us
Viking Therapeutics (VKTX)
NASDAQ:VKTX
VKTX Analyst Ratings
Strong Buy
16 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
VKTX Stock 12 Month Forecast
Average Price Target
$89.88
▲(184.97% Upside)
| Highest Price Target$125.00 | Average Price Target$89.88 | Lowest Price Target$29.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Oppenheimer
$100
Buy
217.06%
Upside
Reiterated
10/07/25
H.C. Wainwright
$102
Buy
223.40%
Upside
Reiterated
09/29/25
Viking Therapeutics: Promising Position in GLP-1 Market with Strategic Growth PotentialValuation and risks to price target achievement. We reiterate our Buy rating and $102 price target. Our valuation is based on contribution from all three clinical stage assets; VK2809, 40.2% contribution (75% chance of success); VK2735, 54.9% contribution (75% chance of success); and VK0214, 4.9% contribution (35% chance of success). Our price target is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug's potential commercial profile.
BTIG
$125
Buy
296.32%
Upside
Reiterated
09/22/25
Viking Therapeutics: Strong Buy Rating Amid Strategic Positioning and Acquisition Potential in the Metabolic Disease MarketWe see today's announced acquisition following Roche's (RHHBY , Not Rated) recent acquisition of 89bio (ETNB, Carmot (RHHBY) for a total value of up to $3.5B and $3.1B respectively as representative of large pharma's strong interest in the obesity and metabolic disease platforms and willingness to pay a premium for acquisitions, providing positive readthroughs to Viking. We view Viking as having one of the few remaining late-stage and class-leading obesity franchises with both oral and subcutaneous programs, with increasing strategic premium given scarcity valuation. We expect this transaction will sharpen Viking's clinical updates and strategic optionality, bolstering sentiment ahead of key clinical readouts.
Piper Sandler
$71
Buy
125.11%
Upside
Reiterated
09/08/25
Citi
$38→$29
Hold
-8.05%
Downside
Reiterated
08/20/25
Morgan Stanley
$98
Buy
210.72%
Upside
Reiterated
08/20/25
Laidlaw
$110
Buy
248.76%
Upside
Reiterated
08/20/25
Leerink Partners
$118
Buy
274.13%
Upside
Reiterated
08/19/25
Truist Financial
$75
Buy
137.79%
Upside
Reiterated
08/19/25
Stifel Nicolaus
$95
Buy
201.20%
Upside
Reiterated
08/19/25
Raymond James
$122
Buy
286.81%
Upside
Reiterated
08/19/25
William Blair
―
Buy
―
Reiterated
08/19/25
J.P. Morgan
―
Buy
―
Reiterated
08/19/25
Maxim Group
$70
Buy
121.94%
Upside
Reiterated
08/19/25
Jefferies
$101
Buy
220.23%
Upside
Reiterated
08/19/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Oppenheimer
$100
Buy
217.06%
Upside
Reiterated
10/07/25
H.C. Wainwright
$102
Buy
223.40%
Upside
Reiterated
09/29/25
Viking Therapeutics: Promising Position in GLP-1 Market with Strategic Growth PotentialValuation and risks to price target achievement. We reiterate our Buy rating and $102 price target. Our valuation is based on contribution from all three clinical stage assets; VK2809, 40.2% contribution (75% chance of success); VK2735, 54.9% contribution (75% chance of success); and VK0214, 4.9% contribution (35% chance of success). Our price target is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug's potential commercial profile.
BTIG
$125
Buy
296.32%
Upside
Reiterated
09/22/25
Viking Therapeutics: Strong Buy Rating Amid Strategic Positioning and Acquisition Potential in the Metabolic Disease MarketWe see today's announced acquisition following Roche's (RHHBY , Not Rated) recent acquisition of 89bio (ETNB, Carmot (RHHBY) for a total value of up to $3.5B and $3.1B respectively as representative of large pharma's strong interest in the obesity and metabolic disease platforms and willingness to pay a premium for acquisitions, providing positive readthroughs to Viking. We view Viking as having one of the few remaining late-stage and class-leading obesity franchises with both oral and subcutaneous programs, with increasing strategic premium given scarcity valuation. We expect this transaction will sharpen Viking's clinical updates and strategic optionality, bolstering sentiment ahead of key clinical readouts.
Piper Sandler
$71
Buy
125.11%
Upside
Reiterated
09/08/25
Citi
$38→$29
Hold
-8.05%
Downside
Reiterated
08/20/25
Morgan Stanley
$98
Buy
210.72%
Upside
Reiterated
08/20/25
Laidlaw
$110
Buy
248.76%
Upside
Reiterated
08/20/25
Leerink Partners
$118
Buy
274.13%
Upside
Reiterated
08/19/25
Truist Financial
$75
Buy
137.79%
Upside
Reiterated
08/19/25
Stifel Nicolaus
$95
Buy
201.20%
Upside
Reiterated
08/19/25
Raymond James
$122
Buy
286.81%
Upside
Reiterated
08/19/25
William Blair
―
Buy
―
Reiterated
08/19/25
J.P. Morgan
―
Buy
―
Reiterated
08/19/25
Maxim Group
$70
Buy
121.94%
Upside
Reiterated
08/19/25
Jefferies
$101
Buy
220.23%
Upside
Reiterated
08/19/25
Best Analysts Covering Viking Therapeutics
1 Month
xxx
Success Rate
13/21 ratings generated profit
Average Return
+12.93%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 61.90% of your transactions generating a profit, with an average return of +12.93% per trade.
3 Months
xxx
Success Rate
12/22 ratings generated profit
Average Return
+20.24%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 54.55% of your transactions generating a profit, with an average return of +20.24% per trade.
1 Year
Success Rate
14/22 ratings generated profit
Average Return
+145.56%
reiterated a buy rating 2 months ago
Copying Naz Rahman's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +145.56% per trade.
2 Years
xxx
Success Rate
15/22 ratings generated profit
Average Return
+216.97%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 68.18% of your transactions generating a profit, with an average return of +216.97% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
VKTX Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
25
18
31
26
18
Buy
5
5
10
7
5
Hold
3
2
3
3
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
33
25
44
36
24
Each month's total comprises the sum of three months' worth of ratings.
VKTX Financial Forecast
VKTX Stock Forecast FAQ
What is VKTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Viking Therapeutics’s 12-month average price target is 89.88.
What is VKTX’s upside potential, based on the analysts’ average price target?
Viking Therapeutics has 184.97% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is VKTX a Buy, Sell or Hold?
Viking Therapeutics has a consensus rating of Strong Buy which is based on 16 buy ratings, 2 hold ratings and 0 sell ratings.
What is Viking Therapeutics’s price target?
The average price target for Viking Therapeutics is 89.88. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $125.00 ,the lowest forecast is $29.00. The average price target represents 184.97% Increase from the current price of $31.54.
The highest analyst price target is $125.00 ,the lowest forecast is $29.00. The average price target represents 184.97% Increase from the current price of $31.54.
What do analysts say about Viking Therapeutics?
Viking Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.
How can I buy shares of VKTX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.